International variation in outcomes among people with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the NAVIGATOR Trial.
<h4>Background</h4> <p>Regional differences in risk of diabetes mellitus and cardiovascular outcomes in people with impaired glucose tolerance are poorly characterized. Our objective was to evaluate regional variation in risk of new-onset diabetes mellitus, cardiovascular outcomes...
Autores principales: | Dos Santos, M, Sharma, A, Sun, J, Pieper, K, McMurray, J, Holman, R, Lopes, R |
---|---|
Formato: | Journal article |
Lenguaje: | English |
Publicado: |
American Heart Association
2017
|
Ejemplares similares
-
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
por: Califf, R, et al.
Publicado: (2008) -
Noncardiovascular deaths are more common than cardiovascular deaths in patients with cardiovascular disease or cardiovascular risk factors and impaired glucose tolerance: Insights from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial.
por: Sharma, A, et al.
Publicado: (2016) -
Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): a cohort analysis.
por: Yates, T, et al.
Publicado: (2014) -
Association between change in daily ambulatory activity and cardiovascular events in people with impaired glucose tolerance (NAVIGATOR trial): A cohort analysis
por: Yates, T, et al.
Publicado: (2014) -
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial
por: Preiss, D, et al.
Publicado: (2012)